Meihua Biotech (600873): The performance in the first half of the year was in line with expectations, and the industry position continued to consolidate and improve

Meihua Biotech reported first-half 2025 revenue of 12.28 billion yuan, down 2.87% year on year, while net income rose 19.96% to 1.768 billion yuan. Growth was driven by a sharp rise in the volume and price of 70% lysine and lower raw material costs, while feed-grade amino acid revenue grew 3.4%.